[Parkinsonism following addition of fluoxetine to the treatment with neuroleptics or carbamazepine].
This article describes three patients who developed parkinsonism when fluoxetine was added to their existing medication (neuroleptics or carbamazepine). Based on published pharmacological and neuroanatomical research we postulate a serotonin-dopamine antagonism to be operative in the development of drug-induced parkinsonism. Alternatively, the possibility of a pharmacokinetic interaction remains.
Touw
D J
DJ
Apotheek Haagse Ziekenhuizen, Den Haag.
Gernaat
H B
HB
van der Woude
J
J
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002220:Carbamazepine / Q000009:adverse effects*; D018492:Dopamine Antagonists; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D012702:Serotonin Antagonists / Q000494:pharmacology
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D012702:Serotonin Antagonists; D005473:Fluoxetine; D002220:Carbamazepine
Parkinsonisme na toevoeging van fluoxetine aan behandeling met neuroleptica of carbamazepine.